Claims for Patent: 6,759,432

Summary for Patent: 6,759,432

Title:	Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction
Abstract:	The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.
Inventor(s):	Khaw; Peng Tee (London, GB), Schultz; Gregory S. (Gainesville, FL)
Assignee:	University of Florida Research Foundation (Gainesville, FL) Moorfields Eye Hospital National Health Service Trust (London, GB) The Institute of Ophthalmology (London, GB)
Application Number:	10/135,934
Patent Claims:	1. A method for treating a human or other mammal to inhibit or prevent contraction of tissue affected with scleroderma or Dupuytren's contracture, said tissue comprising an extracellular matrix component, said method comprising administering to said human or other mammal an effective amount of a matraic metalloprotein inhibitor to inhibit or prevent such contraction. 2. The method of claim 1 wherein said tissue is affected with scleroderma. 3. The method of claim 1 wherein said tissue is affected with Dupuytren's contracture. 4. The method of claim 1 wherein said extracellular matrix inhibitor is a collagenase inhibitor. 5. The method of claim 1 wherein said matrix metalloproteinase inhibitor is capable of inhibiting a matrix metalloproteinase selected from the group consisting of matrix metalloproteinases 1, 2 and 3. 6. The method of claim 1 wherein said matrix metalloproteinase Inhibitor is N-[2(R)-2-(hydroxamido-carbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide. 7. The method of claim 1 wherein said matrix metalloprotinase inhibitor is a peptide hydroxamic acid or a pharmaceutically acceptable derivative thereof. 8. The method of claim 1 wherein said collagenase matrix metalloproteinase inhibitor is administered in combination with at least one other inhibitor. 9. The method of claim 1 wherein said matrix metalloproteinase inhibitor is administered in combination with an inhibitor of a collagen-stimulating cytokine. 10. The method of claim 1 wherein said matrix metalloproteinase inhibitor is administered in combination with a further pharmaceutically active ingredient selected from the group consisting of antibiotics, antifungals, steroids, enzyme inhibitors, epidermal growth factors, fibronectin and aprotinin. 11. The method of claim 1 wherein said matrix metalloproteinase inhibitor is administered as a prophylactic measure.

Details for Patent 6,759,432

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	12/29/1993		2014-03-16
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2014-03-16